TCP
ITCI

Tourbillon Capital Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Tourbillon Capital Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-375,000
Closed -$5.92M – 64
2017
Q3 		$5.92M Buy
+375,000
New +$5.5M 0.14% 47

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tourbillon Capital Partners's ITCI Position: Q4 2017 in Review

Tourbillon Capital Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2017, closing a stake of 375,000 shares — an estimated $5.92M sold.

Tourbillon Capital Partners first reported a position in ITCI in Q3 2017 and held it in 1 quarter. The position peaked at $5.92M in Q3 2017. 131 funds tracked by Wall St. Rank hold ITCI as of Q4 2017.

  • Tourbillon Capital Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2017 after selling out during the quarter.
  • Tourbillon Capital Partners sold 375,000 Intra-Cellular Therapies Inc. shares in Q4 2017, an estimated $5.92M.
  • Tourbillon Capital Partners first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and held it in 1 quarter.
  • Tourbillon Capital Partners's Intra-Cellular Therapies Inc. position peaked at $5.92M in Q3 2017.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2017.

Based on Tourbillon Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.